FDA approves GlaxoSmithKline renal cancer drug

JohnLetzing

SAN FRANCISCO (MarketWatch) -- GlaxoSmithKline
GSK, -1.05%
said Monday that the U.S. Food and Drug Administration has approved the use of its Votrient medication to treat patients with advanced renal cell carcinoma, a form of kidney cancer. Roughly 57,700 people in the U.S. will be diagnosed with kidney cancer this year, the company said, and 13,000 will die from the disease. Votrient is a once-daily, oral medication. Its approval was supported by a unanimous decision by the FDA's oncology drugs advisory committee, GlaxoSmithKline said.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.